Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Immunogen (IMGN) Should Revalue Higher Following IMGN853 ASCO Data, Cantor Fitzgerald Says
-
Immunogen (IMGN) ASCO Data on IMGN853 'Solidifies' Pipeline Potential, Cantor Fitzgerald Says
-
Notable Analyst Rating Changes 3/31: (DHI) (TEVA) (CNDO) Upgraded; (SLB) (DB) (WPT) Downgraded
-
Pre-Open Stock Movers 03/31: (SORL) (MOV) (CHTR) Higher; (GV) (SNTA) (TCK) Lower (more...)
-
Cantor Fitzgerald Upgrades Immunogen Inc. (IMGN) to Buy; Kadcyla Deal Reduces Overhang
-
Immunogen (IMGN) PT Cut to $9 at Cantor Fitzgerald
-
Cantor Fitzgerald Starts Immunogen Inc. (IMGN) at Hold, $15 Target
-
Cantor Fitzgerald Maintains an 'Buy' on ImmunoGen (IMGN); Lowers PT
-
ImmunoGen (IMGN) Says Underwriters Exercised Over-Allotment Option: Total Offer for 10.35M Shares
-
Cantor Fitzgerald Maintains a 'Buy' on ImmunoGen (IMGN); Raises Price Target

